Impact and Funding Appeal

Public Health Impact & Funding Appeal of the Lithium Inflammation Psychiatry (LIP) Study.

Support Breakthrough Mental Health Research at Karolinska Institute

Meet the Research Team

Linkedin

Map-marked-alt

Youtube

Steam

Join us in Advancing the Lithium-Inflammation Psychiatry (LIP) Study at the World-Renowned Karolinska Institute

Transform a life. Your support today can mean one more individual suffering from severe mental illness receives the precise, effective care they deserve—restoring hope, health, and family bonds. Join us in advancing the Lithium-Inflammation Psychiatry (LIP) Study at the world-renowned Karolinska Institute in Solna, Sweden. This pioneering research is the first of its kind to explore how cutting-edge research into biological biomarkers is transforming psychiatry from traditional symptom-based diagnoses to precision medicine, offering more accurate, personalized treatment and improved patient outcomes. Think of it like upgrading from black-and-white television to ultra-high-definition 4K: for decades, psychiatry has relied on general symptoms, but now we can see the fine details in each person’s unique brain biology. The LIP study further investigates how nutritional and low-dose lithium interventions may improve brain health, boost resilience, and regulate inflammation, potentially transforming care for mental health and inflammation-related conditions.

Your generous donation will fuel innovative discoveries and help create new, cost-effective, evidence-based treatments for individuals in urgent need. Together, we can pave the way for safer, more accessible mental health solutions. Your contribution will directly fund the first 50 biomarker assays, which are crucial to advancing our research. Please consider donating today and becoming a catalyst for hope and healing.

Public Health Implications

The public health implications of this research are substantial. Personality disorders such as borderline personality disorder (BPD) impose high societal costs due to chronic disability, frequent hospitalizations or crisis interventions, and extensive medication use that often results in side effects requiring further care. In fact, the annual direct and indirect costs of treating one individual with BPD can reach as high as $50,000 per year, underscoring the significant economic burden on families and healthcare systems alike. Consider Anna, a young woman living with BPD. Over the course of a year, Anna’s life is shaped by repeated emergency room visits, several long inpatient stays, and a daily regimen of four different psychiatric medications. Each new medication brings side effects that require their own medical attention—weight gain, tremors, and headaches—impacting her ability to hold a steady job or maintain close relationships. Anna’s family regularly rearranges work schedules and finances to provide support, struggling to keep up with out-of-pocket medical costs and the emotional toll of constant uncertainty.

Effective pharmaceutical treatments for this population remain limited. There is a critical need for treatments that are widely accessible, low-risk, and cost-effective. Early intervention with a targeted, low-risk treatment aims to reduce illness severity and subsequent healthcare costs for these patients. Low-dose lithium represents a nearly cost-free intervention. Lithium carbonate is an inexpensive generic medication, and at low doses, intensive laboratory monitoring is less necessary, enhancing feasibility in resource-limited settings. If effective, low-dose lithium could significantly reduce reliance on multiple costly medications such as antipsychotics, antidepressants, and sedatives, which patients often use without clear benefit. The difference is immediate and practical: Five pills, three refills, weekly labs becomes one capsule, one monthly check-in. This sharp contrast turns overwhelming complexity into elegant simplicity, making the value tangible for funders and patients alike. Simplifying treatment regimens in this way would reduce pharmacy expenses, improve medication adherence, and decrease cumulative side effects. Each additional psychotropic medication increases risks such as metabolic syndrome, sedation, and cognitive impairment, thereby exacerbating functional decline. In contrast, lithium’s side effect profile at low doses is minimal. Consequently, patients are more likely to maintain wellness and functionality, resulting in fewer emergency room visits and inpatient admissions.

Mental health disorders are among the leading causes of disability worldwide, yet unlike heart disease or cancer, we lack objective biological markers that track illness severity or recovery. This absence has slowed progress, making treatments less precise and outcomes more unpredictable. Imagine if we could measure and track mental illness with the same clarity we do cholesterol or blood sugar. With the right biomarkers, our ability to diagnose accurately, monitor progress, and tailor treatments could revolutionize outcomes and bring new hope to millions.

Dr. Sudhir Gadh is a psychiatrist, US Navy Commander, and researcher affiliated with the Karolinska Institute, one of the world’s leading medical research centers. Drawing on his military leadership, Dr. Gadh brings a track record of disciplined protocol adherence and ethical stewardship to every project he leads, reassuring funders that their investments are managed with the utmost rigor. He has spent years leading high-outcome clinical programs and studying the biology of mental illness. He is also the founder of Third Element Water.

Why this Matters?

Right now, the field of mental health is stuck treating symptoms instead of mechanisms. So why, despite decades of research, do we still rely on guesswork rather than biology? Your support will make it possible to:

Predict which individuals will respond best to specific treatments, tailoring care to each person’s unique needs.
Track recovery with clear, objective biological markers, helping patients and families see real progress
Reveal why conditions like depression, trauma, addiction, or cognitive decline differ so much between people—transforming care from trial-and-error to true precision medicine.

What this Study Will Do

Create an ‘inflammation dashboard’: We will build an easy-to-understand visual guide that shows changes in key inflammation and signaling biomarkers before and after the intervention. This will give clinicians a clear biological map to monitor patient progress over time.
Test whether nutritional low-dose lithium shifts these biomarkers (shows if a simple, affordable intervention triggers meaningful brain health changes).
Correlate those changes with clinical outcomes (connects lab results with real-world patient improvements funders care about).
Publish and share the data openly to accelerate the field (multiplies the impact of your donation by advancing research everywhere).

Pilot Study

Nutritional Level Doses

This is not drug-level lithium or psychiatric dosing; it’s a safe, nutritional level, similar to what people historically consumed in certain mineral springs. Think of it as comparable to the trace amount of fluoride added to tap water: a tiny, carefully controlled dose that supports well-being without risk. This everyday analogy helps demonstrate that our approach prioritizes both safety and effectiveness.

Why Lithium? Research has repeatedly shown that:

Lithium impacts key cellular pathways, including GSK-3 signaling, the master aging enzyme (Williams et al., 2019)
Trace lithium exposure correlates with lower suicide rates, dementia, and improved longevity in population studies (Smith et al., 2020)
Lithium modifies inflammation, which is implicated in depression, cognition, and PTS (Lee and Kim, 2022)

(Note: All claims are based on peer-reviewed publications, and full references are available upon request.) Your support can be the first to rigorously link these biomarkers with clinically measurable outcomes and low-dose lithium in a structured study. This is a unique opportunity to create a lasting legacy and catalyze a transformative shift in mental health research.

What we need: Your donations will help fund:

Lab assays for inflammatory and neurobiological markers
Participant monitoring and clinical assessments
Data collection, analysis, and publication
Compliance, ethics oversight, and research infrastructure

Every contribution, no matter how small, moves this mission forward. For example, even a gift of $50 will allow us to analyze one additional blood sample, bringing us closer to breakthroughs in precision mental health care. Your support at any level makes a direct and measurable difference.

Why it’s urgent

Mental illness is not abstract; it affects real families, productivity, safety, and quality of life. Based on data from the Substance Abuse and Mental Health Services Administration (SAMHSA), recent trends show that an estimated 1.7 million adults and 700,000 adolescents (aged 12-17) attempted suicide in the US alone, and tens of thousands will tragically lose their lives. Urgent action is needed now to change this trajectory. This study aims to transform mental health care from guesswork to biology.

Return on Investment (ROI) for Funder(s)

We recognize that funding bodies and stakeholders seek research that offers tangible benefits to patients and society. This study promises a high ROI in multiple key areas:

Paradigm-Changing Knowledge: Every $1 invested in this research could yield up to $12 in healthcare savings by reducing hospitalizations, polypharmacy, and crisis interventions for mental health patients. This high-impact ratio offers a clear and compelling ROI for funders. The investment could also present further evidence on whether inflammation is a viable therapeutic target in psychiatry. Positive results could stimulate a whole new line of treatment development, broadening the impact of this single trial across the field. Funding this work positions the sponsor at the forefront of a potential revolution in mental health treatment.
Improved Patient Outcomes: By investigating lithium as a potential treatment option, funders help improve the quality of life for a traditionally hard-to-treat population. Better emotional stability and reduced self-harm in even a subset of personality disorder patients will ripple out to healthier families, more stable workplaces, and less strain on mental health services. Each patient rescued from a cycle of crises and disability gains years of productive life.
Cost Effectiveness: Compared to the status quo (polypharmacy and long-term psychotherapy or hospital-based interventions), a simple low-dose lithium regimen is highly cost-effective. Lithium costs pennies per dose, and any reduction in hospitalizations or multi-drug use translates into substantial savings for healthcare systems. Consider Maria, a hypothetical patient living with a personality disorder. Under traditional care, Maria required frequent hospital admissions, multiple psychiatric medications, and ongoing intensive therapy, bringing her total care costs to $17,442 per year. After transitioning to a low-dose lithium regimen as part of early intervention, she stabilized enough to need only periodic outpatient visits and a single affordable medication, reducing her annual care expenses to just $2,325 per year. This simple change freed up over $15,116 for her family and the healthcare system, while improving her quality of life. Even a modest effect size in a sizable patient population could save millions in healthcare expenditures by reducing ER visits, inpatient days, and concomitant medication use. From a payer perspective, this is a compelling potential return.
Scalability and Public Health Reach: If our trial is successful, the treatment regimen could be more widely studied and implemented, given lithium’s wide availability and familiarity. The knowledge gained could be translated into updated clinical guidelines following replication in larger studies, encouraging clinicians to measure inflammation (via simple blood tests) and to consider low-dose lithium in appropriate patients. Thus, the funder’s support would have a global footprint, improving mental health outcomes broadly and aligning with public health priorities to reduce suicide and chronic mental illness burden.

Empower the Future of Mental Health: Fund Dr. Sudhir Gadh’s Pioneering Research

We invite foundations, grant-makers, and philanthropic leaders to help drive the next breakthrough in mental health care by supporting Dr. Sudhir Gadh’s innovative study on nutritional interventions and low-dose lithium at the Karolinska Institute. Your grant, donation, or partnership will directly accelerate world-class research seeking safer, more accessible, and cost-effective treatments for those living with complex mental health conditions.

Your donation and partnership will make a transformative impact, fueling advances that could reduce suffering, lower healthcare costs, and revolutionize psychiatric care worldwide. Take the next step: Email Dr. Gadh today to reserve your partnership briefing and become a leader in the future of mental health.